Source: http://www.google.es/patents/US8119680?dq=flatulence
Timestamp: 2013-05-25 20:19:04
Document Index: 766161373

Matched Legal Cases: ['Application No. 2525547', 'Application No. 04752297', 'Application No. 200507305', 'Application No. 2004247013', 'Application No. 2006', 'Application No. 4753', 'Application No. 04752297']

Patente US8119680 - α-Haloketone derivatives of imidazolyl-substituted aromatic compounds and ... - Google PatentesB�squeda Im�genes Maps Play YouTube Noticias Gmail Drive M�s » B�squeda avanzada de patentes | Historial web | Iniciar sesi�n B�squeda avanzada de patentesPatentesNovel compounds, compositions, and kits are provided. Methods of modulating Aβ levels, and methods of treating a disease associated with aberrant Aβ levels are also provided....http://www.google.es/patents/US8119680?utm_source=gb-gplus-sharePatente US8119680 - α-Haloketone derivatives of imidazolyl-substituted aromatic compounds and compounds prepared therefrom N�mero de publicaci�nUS8119680 B2Tipo de publicaci�nConcesi�n N�mero de solicitud12/875,935 Fecha de publicaci�n21 Feb 2012 Fecha de presentaci�n3 Sep 2010 Fecha de prioridad14 May 2003Tambi�n publicado comoCA2525547A1CA2525547CCN102584813AEP1628666A2EP1628666A4US7244739US7781442US7799808US8017629US20050070538US20070249833US20070260058US20100324032US20100331551WO2004110350A2WO2004110350A3 InventoresGuity P BalowSoan ChengDaniel D ComerLong MaoDavid Pleynet Cesionario originalNeurogenetic Pharmaceuticals, Inc. Clasificaci�n de EE.UU.514/399548/341.1 Clasificaci�n internacionalA61K31/415A61K31/425A61K31/40A61K31/53A61K31/505A61K31/497A61K31/535C07D277/42C07D417/04C07D417/14C07D277/04A61K31/50C07D417/10C07D413/00C07D233/54A61KC07D417/12 Clasificaci�n cooperativaC07D417/12C07D417/04C07D277/42C07D417/10C07D417/14 Clasificaci�n europeaC07D 417/12C07D 277/42C07D 417/10C07D 417/14C07D 417/04ReferenciasCitas de patentes (80)Otras citas (41)Enlaces externosUSPTO Cesi�n de USPTO Espacenetα-Haloketone derivatives of imidazolyl-substituted aromatic compounds and compounds prepared therefromUS 8119680 B2 Resumen Novel compounds, compositions, and kits are provided. Methods of modulating Aβ levels, and methods of treating a disease associated with aberrant Aβ levels are also provided.
Citas de patentes Patente citada Fecha de presentaci�n Fecha de publicaci�n Solicitante T�tuloUS371079529 Sep 197016 Ene 1973Alza Corp,UsDrug-delivery device with stretched, rate-controlling membraneUS40441269 Jul 197623 Ago 1977Allen & Hanburys LimitedSteroidal aerosol compositions and process for the preparation thereofUS432824513 Feb 19814 May 1982Syntex (U.S.A.) Inc.Carbonate diester solutions of PGE-type compoundsUS435860316 Abr 19819 Nov 1982Syntex (U.S.A.) Inc.Acetal stabilized prostaglandin compositionsUS436492330 Abr 198121 Dic 1982Allen & Hanburs LimitedChemical compoundsUS440923921 Ene 198211 Oct 1983Syntex (U.S.A.) Inc.Propylene glycol diester solutions of PGE-type compoundsUS441054510 May 198218 Oct 1983Syntex (U.S.A.) Inc.Carbonate diester solutions of PGE-type compoundsUS441420913 Jun 19778 Nov 1983Allen & Hanburys LimitedMicronized aerosol steroidsUS476621316 Ene 198723 Ago 1988Merck Patent Gesellschaft Mit Beschrankter Haftung1,4-dihydropyridinesUS503325230 Jul 199023 Jul 1991Entravision, Inc.Method of packaging and sterilizing a pharmaceutical productUS505255827 Jul 19901 Oct 1991Entravision, Inc.Packaged pharmaceutical productUS532390715 Mar 199328 Jun 1994Multi-Comp, Inc.Child resistant package assembly for dispensing pharmaceutical medicationsUS538774217 Jun 19917 Feb 1995Scios Nova Inc.Transgenic mice displaying the amyloid-forming pathology of alzheimer's diseaseUS559401017 Jun 199414 Ene 1997Bayer AktiengesellschaftSubstituted monopyridylmethyl derivativesUS56124861 Nov 199318 Mar 1997Athena Neurosciences, Inc.Transgenic animals harboring APP allele having swedish mutationUS567280518 Jul 199130 Sep 1997The Regents Of The University Of CaliforniaTransgenic mice expressing the neurotoxic C-terminus of β-amyloid precursor proteinUS57098743 Jun 199620 Ene 1998Emory UniversityDevice for local drug delivery and methods for using the sameUS57595425 Ago 19942 Jun 1998New England Deaconess Hospital CorporationCompositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseasesUS58116337 Jun 199522 Sep 1998Wadsworth; SamuelTransgenic mouse expressing APP.sub.770US58406741 Ago 199624 Nov 1998Oregon Health Sciences UniversityCovalent microparticle-drug conjugates for biological targetingUS585000322 Ene 199715 Dic 1998Athena NeurosciencesTransgenic rodents harboring APP allele having swedish mutationUS58609577 Feb 199719 Ene 1999Sarcos, Inc.Multipathway electronically-controlled drug delivery systemUS59002526 Nov 19924 May 1999Eurand International S.P.A.Method for targeted and controlled release of drugs in the intestinal tract and more particularly in the colonUS594843321 Ago 19977 Sep 1999Bertek, Inc.Transdermal patchUS597236617 Sep 199626 Oct 1999The Unites States Of America As Represented By The Secretary Of The ArmyDrug releasing surgical implant or dressing materialUS598313412 Jun 19989 Nov 1999Electromagnetic Bracing Systems Inc.Electrophoretic cuff apparatus drug delivery systemUS59853072 Dic 199716 Nov 1999Emory UniversityDevice and method for non-occlusive localized drug deliveryUS59853176 Sep 199616 Nov 1999Theratech, Inc.Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agentsUS600453418 Abr 199721 Dic 1999Massachusetts Institute Of TechnologyTargeted polymerized liposomes for improved drug deliveryUS601071521 Oct 19974 Ene 2000Bertek, Inc.Transdermal patch incorporating a polymer film incorporated with an active agentUS602497512 Nov 199615 Feb 2000Americare International Diagnostics, Inc.Method of transdermally administering high molecular weight drugs with a polymer skin enhancerUS603752114 Nov 199414 Mar 2000Hoechst Japan LimitedTransgenic mouse expressing an β-Amyloid transgeneUS603997520 Sep 199621 Mar 2000Hoffman-La Roche Inc.Colon targeted delivery systemUS604873630 Dic 199811 Abr 2000Kosak; Kenneth M.Cyclodextrin polymers for carrying and releasing drugsUS606008218 Abr 19979 May 2000Massachusetts Institute Of TechnologyPolymerized liposomes targeted to M cells and useful for oral or mucosal drug deliveryUS60714952 Oct 19976 Jun 2000Imarx Pharmaceutical Corp.Targeted gas and gaseous precursor-filled liposomesUS61207518 Sep 199719 Sep 2000Imarx Pharmaceutical Corp.Charged lipids and uses for the sameUS613157030 Jun 199817 Oct 2000Aradigm CorporationTemperature controlling device for aerosol drug deliveryUS61398651 Oct 199731 Oct 2000Eurand America, Inc.Taste-masked microcapsule compositions and methods of manufactureUS616730129 Ago 199526 Dic 2000Lincoln Fair Lawn AssociatesIontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuitUS61844357 Jun 19956 Feb 2001Advanced Research And Technology InstituteTransgenic mouse expressing APP770-V717FUS618779722 Dic 199713 Feb 2001Dupont Pharmaceuticals CompanyPhenyl-isoxazoles as factor XA InhibitorsUS618799211 Mar 199913 Feb 2001Merck & Co., Inc.Transgenic mouse having a disrupted amyloid precursor protein geneUS621142828 Ago 19953 Abr 2001Merck & Co., Inc.Transgenic mouse expressing a familial form of human amyloid precursor proteinUS625387223 May 19973 Jul 2001Gmundner Fertigteile Gesellschaft M.B.H & Co., KgTrack soundproofing arrangementUS62565339 Jun 19993 Jul 2001The Procter & Gamble CompanyApparatus and method for using an intracutaneous microneedle arrayUS626159529 Feb 200017 Jul 2001Zars, Inc.Transdermal drug patch with attached pocket for controlled heating deviceUS626798326 Oct 199831 Jul 2001Bando Chemical Industries, Ltd.Dermatological patch and process for producing thereofUS627135914 Abr 19997 Ago 2001Musc Foundation For Research DevelopmentTissue-specific and pathogen-specific toxic agents and ribozymesUS627455210 Nov 199714 Ago 2001Cytimmune Sciences, Inc.Composition and method for delivery of biologically-active factorsUS63166526 Jun 199513 Nov 2001Steliou KostaDrug mitochondrial targeting agentsUS63407833 Oct 199622 Ene 2002University Of WashingtonRodent models of human amyloidosesUS656281726 Ene 199913 May 2003Shionogi & Co., Ltd.Tricyclic compoundUS2003015819925 Ene 200221 Ago 2003Kylix, B.V.Novel compounds for inhibition of Tie-2USRE2881916 Abr 197518 May 1976Syntex (U.S.A.) Inc.Dialkylated glycol compositions and medicament preparations containing sameEP0219436A216 Oct 198622 Abr 1987Mitsubishi Kasei CorporationThiazole derivative and leukotriene antagonist containing the same as the effective ingredientsEP1052238A126 Ene 199915 Nov 2000SHIONOGI &amp; CO., LTD.Novel tricyclic compoundJP1143856A T�tulo no disponibleJP4276551A T�tulo no disponibleJP7048369A T�tulo no disponibleJP62181277A T�tulo no disponibleJP2001114690A T�tulo no disponibleJP2002121597A T�tulo no disponibleJP2002531503A T�tulo no disponibleJP2002531504A T�tulo no disponibleJP2003313176A T�tulo no disponibleJP2004516507A T�tulo no disponibleJP2006500325A T�tulo no disponibleWO1997036898A11 Abr 19979 Oct 1997Anthony, Neville, J.Inhibitors of farnesyl-protein transferaseWO1999038829A126 Ene 19995 Ago 1999Haga, NobuhiroNovel tricyclic compoundWO2000033841A17 Dic 199915 Jun 2000Lago, Maria, A.Myt1 kinase inhibitorsWO2000033842A17 Dic 199915 Jun 2000Lago, Maria A.Myt1 kinase inhibitorsWO2001087845A214 May 200122 Nov 2001Fujisawa Pharmaceutical Co., Ltd.N-containing heterocyclic compounds and their use as 5-ht antagonistsWO2002050591A119 Dic 200127 Jun 2002Teradyne, Inc.Methods and apparatus for controlling access to an optical interfaceWO2002083667A210 Abr 200224 Oct 2002Cao, JingrongInhibitors of c-jun n-terminal kinases (jnk) and other protein kinasesWO2003007955A222 Jul 200230 Ene 2003Cancer Research Technology LimitedBiphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancerWO2003032916A216 Oct 200224 Abr 2003Brady, Thomas, P.Organosulfur inhibitors of tyrosine phosphatasesWO2004002480A127 May 20038 Ene 2004Novo Nordisk A/SNovel glucagon antagonists/inverse agonistsWO2004016997A126 Jun 200326 Feb 2004Atrey, Milind, DiwakarOil carry-over prevention from helium gas compressorWO2004046120A217 Nov 20033 Jun 2004Arnost, MichaelDiaminotriazoles useful as inhibitors of protein kinasesOtras citasReferencia1Canadian Office Action dated Jun. 29, 2010 for Application No. 2525547 .2Dhar et al., A Survey of Cyclic Replacements for the Central Diamide Moiety of Inhibitors of Inosine Monophosphate Dehydrogenase. Bioorganic & Medicinal Chemistry Letters, 12:3125-3128 (2002).3Emilien et al., Prospects for Pharmacological Intervention in Alzheimer Disease, Arch Neuro., 57:176-181 (2000).4European Search Report dated Nov. 7, 2007 for EP Application No. 04752297.4.5Examination Report dated Jan. 30, 2006 for SG Application No. 200507305-1.6Examiner's Report dated Oct. 15, 2009 for AU Application No. 2004247013.7Games et al., Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein, Nature 373:523-527 (1995).8Games et al., Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein, Nature 373:523-527 (1995).9Hampel et al, Synthese einiger 2-Alkylamino- und 2-Arylamino-4-aryl-thiazole. Journal fur Praktische Chemie, 1968, 38(5-6):320-326.10Harris et al., Discovery and evaluation of 2-Anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors, Journal of Medicinal Chemistry, Web release Feb. 9, 2005.11International Search Report and Written Opinion dated Dec. 20, 2004 for PCT Application No. PCT/US04/15239.12Japanese Office Action dated Jun. 1, 2010 for Application No. 2006-533094, English Translation.13Joshi et al., Synthesis of Some Substituted Pyrazoles as Possible Antibacterial Agents, J. Indian Chem. Soc., vol. LIV, pp. 1081-1083 (1977).14Joshua et al, Interaction of Thiocarbamides with alpha-Bromoketones: Formation of Substituted 2-Aminothiazoles, Indian Journal of Chemistry, 1973, 11(2):118-119.15Joshua et al, Interaction of Thiocarbamides with α-Bromoketones: Formation of Substituted 2-Aminothiazoles, Indian Journal of Chemistry, 1973, 11(2):118-119.16Klunk et al., Imaging Abeta Plaques in Living Transgenic Mice with Multiphoton Microscopy and Methoxy-X04, a Systematically Administered Congo Red Derivative, J. Neuropathol. Exp. Neurol., 61:797-805 (2002).17Klunk et al., Imaging Aβ Plaques in Living Transgenic Mice with Multiphoton Microscopy and Methoxy-X04, a Systematically Administered Congo Red Derivative, J. Neuropathol. Exp. Neurol., 61:797-805 (2002).18Lubisch et al. CAS: 135: 166828, 2001.19Mathis et al., A Lipophilic Thioflavin-T Derivative for Positron emission tomography (PET) Imaging of Amyloid in Brain, Bioorg. Med. Chem. Lett., 12:295-298 (2002).20Mishina et al. CAS: 123:83361, 1995.21Nagatomi et al, Studies on the Anti-inflammatory Activity and Ulcerogenic Adverse Effect of Thiazole Derivatives, Especially 2-Amino-thiazoleacetic Acid Derivatives, Arzneiitte1-Forschung Druq Research, 1984, 34(5):599-603.22Neve et al., Transgenic Mice Expressing APP-C100 in the Brain, Neurobiol. Aging, 17:191-203 (1996).23Office Action dated Sep. 22, 2006 for IN Application No. 4753/DELNP/2005.24Official Action for European Application No. 04752297.4 dated Nov. 30, 2010.25Pruitt et al., CAS: 134:375528 (2001).26Reddy et al, Activity of Acryloyl Thaiazoles, Thiazolyl Aminopyrimidines and Thiazolyl Thiopyrmidines on Aspergillus flavus Link, ex Fries In Vitro, Indian Bot. Reptr 4(2):144-147 (1985).27Schumann et al, Synthesis and Characterization of Some Heterocyclic Analogues of N.N′-Perarylated Phenylen-1,4-diamines and Benzidines as a New Class of Hole Transport materials, Synthesis, 2002, No. 9, pp. 1268-1276.28Schumann et al, Synthesis and Characterization of Some Heterocyclic Analogues of N.N'-Perarylated Phenylen-1,4-diamines and Benzidines as a New Class of Hole Transport materials, Synthesis, 2002, No. 9, pp. 1268-1276.29US Notice of Allowance dated Apr. 16, 2010 for U.S. Appl. No. 11/779,249.30US Notice of Allowance dated Apr. 29, 2011 in U.S. Appl. No. 12/861,782.31US Notice of Allowance dated Feb. 6, 2007 for U.S. Appl. No. 10/846,841.32US Notice of Allowance dated May 5, 2010 for U.S. Appl. No. 11/765,397.33US Office Action dated Dec. 2, 2009 for U.S. Appl. No. 11/779,249.34US Office Action dated Dec. 30, 2009 for U.S. Appl. No. 11/765,397.35US Office Action dated Jun. 18, 2009 for U.S. Appl. No. 11/765,397.36US Office Action dated May 22, 2009 for U.S. Appl. No. 11/779,249.37US Office Action dated Oct. 16, 2006 for U.S. Appl. No. 10/846,941.38Wiltfang et al., Elevation of beta-Amyloid Peptide 2-42 in Sporadic and Familial Alzheimer's Disease and Its Generation in PS1 Knockout Cells, J. Biol. Chem., 276:42645-42657 (2001).39Wiltfang et al., Elevation of β-Amyloid Peptide 2-42 in Sporadic and Familial Alzheimer's Disease and Its Generation in PS1 Knockout Cells, J. Biol. Chem., 276:42645-42657 (2001).40Written Opinion dated Jul. 4, 2006 for SG App. No. 200507305-1.41Written Opinion dated May 2, 2007 for SG App. No. 200507305-1.GirarImagen originalP�gina principal de Google - Sitemap - Descargas masivas de USPTO - Pol�tica de privacidad - Condiciones de servicio - Acerca de Google Patentes - Danos tu opini�nDatos proporcionados por IFI CLAIMS Patent Services©2012 Google